IU Simon Cancer Center Researchers Lead Ovarian Cancer Clinical Trial

Main Category: Ovarian Cancer
Also Included In: Clinical Trials / Drug Trials;  Cancer / Oncology
Article Date: 18 Dec 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Article Opinions: 1 posts

Researchers at the Indiana University Melvin and Bren Simon Cancer Center are conducting a novel clinical trial that may reverse the resistance that frequently develops to the most common drug for treating recurrent ovarian cancer.

Over time, many ovarian cancer patients can become resistant to the drug carboplatin, which is the best treatment option for recurrent disease.

Daniela Matei, M.D., associate professor of medicine at the Indiana University School of Medicine and a researcher with the IU Simon Cancer Center, is looking into ways to make patients with recurrent ovarian cancer that have developed a resistance to the platinum-based carboplatin sensitive again to platinum.

In a novel phase 2 clinical trial sponsored by the National Cancer Institute, Dr. Matei; Kenneth Nephew, Ph.D., professor of medical sciences, cellular and integrative physiology, and obstetrics and gynecology at the IU School of Medicine and a researcher with the IU Simon Cancer Center; and colleagues will treat patients with recurrent ovarian cancer with a combination of carboplatin and decitabine.

"The idea behind the trial is to try to make tumors that are resistant to carboplatin sensitive to platinum again by using an additional drug, decitabine," Dr. Matei said. "Decitabine works directly on the DNA and causes demethylation, a chemical modification, of the DNA," Dr. Matei said. "We hope this process makes the tumors sensitive again to platinum."

Women ages 18 and older who have recurrent epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube cancer are eligible to participate.

Patients interested in participating may contact Nancy Menning, R.N., at (317) 274-1658.

For more information about clinical trials at the IU Simon Cancer Center, visit http://www.cancer.iu.edu/cancer/trials.

IU Simon Cancer Center

Article adapted by Medical News Today from original press release.
Visit our ovarian cancer section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
IU Simon Cancer Center. "IU Simon Cancer Center Researchers Lead Ovarian Cancer Clinical Trial." Medical News Today. MediLexicon, Intl., 18 Dec. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/133305.php>

APA
IU Simon Cancer Center. (2008, December 18). "IU Simon Cancer Center Researchers Lead Ovarian Cancer Clinical Trial." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/133305.php.

Please note: If no author information is provided, the source is cited instead.


Ovarian Cancer

Most Popular Articles



Follow Our Ovarian Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Ovarian Cancer Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »